following a full submission:
maribavir (Livtencity®) is accepted for use within NHSScotland.
Indication under review: treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT). Consideration should be given to official guidance on the appropriate use of antiviral agents.
In a phase III study, maribavir significantly improved confirmed CMV viraemia clearance at Week 8 compared with investigator-assigned therapy in patients with refractory CMV infection who had undergone HSCT or SOT.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice357KB (PDF)
Medicine details
- Medicine name:
- maribavir (Livtencity)
- SMC ID:
- SMC2576
- Indication:
The treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 October 2023